Table 9 Previously reported Zn-MOFs’ antimicrobial activity summary.
Samples | S. aureus | E. coli | Concentration | Reference | Note |
|---|---|---|---|---|---|
MOF-5 | 10 | – | 50 mg/mL | Ac; activated1 MOF-5 ([Zn4O(BDC)3].(DMF)9), Zn-MOF(A) ([Zn3(BDC)3(H2O)3].4DMF) and TMU-3 ([HDMA]2[Zn2(BDC)3(DMA)2].6DMF) where BDC: benzene1,4-dicarboxylic acid, HDMA: dimethylammonium and DMA: dimethylamine Zn-MOF(B): 2-Aminoterephthalic acid and 1,4-bis(4-pyridyl)-2,3-diaza-1,3-butadiene linkers | |
Ac MOF-5 | 16 | 10 | |||
Zn-MOF(A) | 15.5 | 14 | |||
Ac Zn-MOF(A) | 16 | 14 | |||
TMU-3 | 10 | 10 | |||
Ac TMU-3 | 14 | 12 | |||
Zn-MOF(B) | 9 | R | 8 mg/mL | ||
Ag/Zn-MOF (1) | 12 | 11 | 8 mg/mL | ||
Ag/Zn-MOF (2) | 10 | 9 | |||
Ag/Zn-MOF (3) | 9 | R | |||
Zn-IP MOF | 28 | 30 | 10 mg/ml | This work |
